Arbutus Biopharma Corp 8-K Filing
Ticker: ABUS · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Arbutus Biopharma Corp (ticker: ABUS) to the SEC on Dec 11, 2025.
How long is this filing?
Arbutus Biopharma Corp's 8-K filing is 3 pages with approximately 776 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 776 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2025-12-11 08:00:44
Filing Documents
- f8k_121025.htm (8-K) — 23KB
- exh_991.htm (EX-99.1) — 26KB
- exh991_01.jpg (GRAPHIC) — 117KB
- exh991_02.jpg (GRAPHIC) — 156KB
- exh991_03.jpg (GRAPHIC) — 170KB
- exh991_04.jpg (GRAPHIC) — 173KB
- exh991_05.jpg (GRAPHIC) — 157KB
- exh991_06.jpg (GRAPHIC) — 147KB
- exh991_07.jpg (GRAPHIC) — 126KB
- exh991_08.jpg (GRAPHIC) — 120KB
- exh991_09.jpg (GRAPHIC) — 198KB
- exh991_10.jpg (GRAPHIC) — 132KB
- exh991_11.jpg (GRAPHIC) — 196KB
- exh991_12.jpg (GRAPHIC) — 126KB
- exh991_13.jpg (GRAPHIC) — 155KB
- exh991_14.jpg (GRAPHIC) — 140KB
- exh991_15.jpg (GRAPHIC) — 118KB
- exh991_16.jpg (GRAPHIC) — 133KB
- exh991_17.jpg (GRAPHIC) — 171KB
- exh991_18.jpg (GRAPHIC) — 148KB
- exh991_19.jpg (GRAPHIC) — 162KB
- 0001171843-25-007879.txt ( ) — 4132KB
- abus-20251211.xsd (EX-101.SCH) — 3KB
- abus-20251211_lab.xml (EX-101.LAB) — 33KB
- abus-20251211_pre.xml (EX-101.PRE) — 22KB
- f8k_121025_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 11, 2025, Lindsay Androski, Chairperson, Chief Executive Officer and President of Arbutus Biopharma Corporation (the "Company") will give a presentation regarding the Company's ongoing lawsuits against Moderna Therapeutics, Inc., Pfizer Inc. and BioNTech SE, for their use of the Company's patented lipid nanoparticle technology in their COVID-19 vaccines ("LNP Litigation"), as part of Roivant Sciences Ltd.'s 2025 Investor Day. The LNP Litigation slides that Ms. Androski will present are filed herewith as Exhibit 99.1 and are incorporated by reference herein. The LNP Litigation slides contain forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements).
Forward-looking statements in the LNP Litigation slides include statements about the Company's plans with respect to the
Forward-looking statements in the LNP Litigation slides include statements about the Company's plans with respect to the ongoing patent litigation matters, and the expected timing thereof. With respect to the forward-looking statements contained in the LNP Litigation slides, the Company has made numerous assumptions regarding the LNP Litigation. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained therein. Known risk factors include, among others: uncertainties associated with litigation generally and patent litigation specifically; economic and market conditions may worsen; market shifts may require a change in strategic focus; and risks related to the sufficiency of the Company's cash resources for its foreseeable and unforeseeable operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears in the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements in the LNP Litigation slides are qualified in their entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained in the LNP Litigation slides to reflect future results, events or developments, except as required by law.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Presentation by Lindsay Androski on December 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: December 11, 2025 By: /s/ Tuan Nguyen Name: Tuan Nguyen Title: Chief Financial Officer